Get the Stockscreener App
11.93
2.29%
-0.28
Pre-market:
12.01
0.08
+0.67%
Intellia Therapeutics Inc stock is traded at $11.93, with a volume of 3.92M.
It is down -2.29% in the last 24 hours and down -0.75% over the past month.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
See More
Previous Close:
$12.21
Open:
$11.9
24h Volume:
3.92M
Relative Volume:
0.86
Market Cap:
$1.67B
Revenue:
$67.67M
Net Income/Loss:
$-412.69M
P/E Ratio:
-3.1177
EPS:
-3.8266
Net Cash Flow:
$-395.87M
1W Performance:
-5.91%
1M Performance:
-0.75%
6M Performance:
-11.43%
1Y Performance:
+5.67%
1-Day Range:
$11.66
$11.96
1-Week Range:
$11.66
$12.96
52-Week Range:
$7.95
$28.25
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Name
Intellia Therapeutics Inc
Sector
Industry
Phone
857-285-6200
Address
40 ERIE STREET, CAMBRIDGE, MA
Compare NTLA vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
11.93 | 1.67B | 67.67M | -412.69M | -395.87M | -3.8266 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 130.42B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 81.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 61.56B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.54B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 43.59B | 742.00K | -1.37B | -1.07B | -7.0731 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-26 | Upgrade | William Blair | Mkt Perform → Outperform |
| Nov-12-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Nov-11-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-07-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-28-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-28-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-27-25 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-27-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-06-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Apr-21-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-05-25 | Initiated | H.C. Wainwright | Buy |
| Feb-28-25 | Downgrade | Goldman | Neutral → Sell |
| Feb-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-27-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-23-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Apr-13-23 | Initiated | Canaccord Genuity | Buy |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Mar-14-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-24-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-19-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Sep-01-22 | Initiated | Citigroup | Sell |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Jun-16-22 | Initiated | BofA Securities | Buy |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Feb-18-22 | Initiated | William Blair | Outperform |
| Feb-07-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-22 | Initiated | Cowen | Outperform |
| Jan-07-22 | Initiated | Piper Sandler | Overweight |
| Oct-05-21 | Initiated | Guggenheim | Buy |
| Sep-24-21 | Initiated | Stifel | Buy |
| Jun-28-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-11-21 | Initiated | H.C. Wainwright | Buy |
| May-07-21 | Upgrade | ROTH Capital | Neutral → Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Outperform |
| Mar-04-21 | Initiated | JMP Securities | Mkt Outperform |
| Dec-22-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-27-20 | Initiated | Truist | Buy |
| Oct-14-20 | Initiated | Wells Fargo | Overweight |
| Sep-18-20 | Initiated | Goldman | Buy |
| Feb-28-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-14-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-01-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-09-19 | Initiated | Robert W. Baird | Outperform |
| Jun-10-19 | Initiated | ROTH Capital | Neutral |
| May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Nov-02-18 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-29-18 | Initiated | Credit Suisse | Neutral |
| Sep-21-18 | Initiated | Raymond James | Mkt Perform |
| May-15-18 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Mar-08-18 | Initiated | JMP Securities | Mkt Outperform |
| Nov-01-17 | Reiterated | Jefferies | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
| Aug-05-16 | Upgrade | Jefferies | Hold → Buy |
View All
Intellia Therapeutics Inc Stock (NTLA) Latest News
NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late - Stocktwits
Cathie Wood’s ARK adds Intellia stock, trims Brera Holdings - Investing.com
Intellia Therapeutics (NTLA) Secured a Facility for Up to $400M. Is It Worth the Cost? - Yahoo Finance
H.C. Wainwright reiterates Intellia stock rating on FDA review progress By Investing.com - Investing.com Nigeria
Intellia’s Lonvo-z Gains FDA Priority Review for HAE - The Globe and Mail
symbol__ Stock Quote Price and Forecast - CNN
Intellia Therapeutics Price Target Maintained With a $25.00/Share by HC Wainwright & Co. - Moomoo
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug - Yahoo Finance
NTLA Reiterates by Citizens -- Price Target Maintained at $30 - GuruFocus
FDA to Decide on First In Vivo Gene Editor Next Year - GenomeWeb
Intellia Therapeutics Stock Short Interest Rises to 40.35% - Quiver Quantitative
NTLA Maintained by Wedbush -- Price Target Raised to $13.00 - GuruFocus
H.C. Wainwright reiterates Intellia stock rating on FDA review progress - Investing.com
NTLA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
Citizens reiterates Intellia stock rating on FDA priority review By Investing.com - Investing.com Canada
Citizens reiterates Intellia stock rating on HAE opportunity potential By Investing.com - Investing.com Nigeria
Intellia Announces FDA Acceptance of BLA for Lonvo-z with PDUFA Date March 10, 2027 - TradingView
Intellia Therapeutics Obtains $400M Senior Secured Credit Facility (NASDAQ: NTLA) - Kalkine Media
Intellia’s one-shot CRISPR therapy gets March 2027 FDA decision date - AllSci
Intellia Therapeutics stock jumps on FDA priority review By Investing.com - Investing.com Nigeria
Intellia Therapeutics Says FDA Accepts Lonvo-z BLA for Hereditary Angioedema - marketscreener.com
Why is Intellia Therapeutics stock rallying today? By Investing.com - Investing.com Australia
NTLA Looks 4.8% Undervalued on GF Value™ Amid FDA Priority Review - GuruFocus
Cathie Wood’s Biotech Bet Intellia Secured An FDA Priority Review For Rare Genetic Disorder Therapy – Retail Sees Upside In NTLA’s Platform - Stocktwits
Why is Intellia Therapeutics stock rallying today? - Investing.com
Intellia stock rises on FDA priority review (NTLA:NASDAQ) - Seeking Alpha
NTLA Looks 4.0% Undervalued on GF Value™ as FDA Advances Lonvo-z Review - GuruFocus
Intellia Therapeutics Shares Rise as FDA Grants Priority Review to Lonvo-z - Yahoo Finance
Intellia Therapeutics stock jumps on FDA priority review - Investing.com
If approved, a one-time treatment could be the world's first in-body gene-editing therapy for hereditary angioedema. - stocktitan.net
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE) - Intellia Therapeutics
FDA grants lonvo-z priority review - CRISPR Medicine News
8-K: Intellia Therapeutics | 8-K: Current report - Moomoo
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates - Eastern Progress
Intellia Therapeutics, Inc. | NTLA Stock Price & Real-time Quotes - finance.biggo.com
NTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapy - Stocktwits
Intellia Locks In $400 Million OrbiMed Loan Tied to HAE Drug Milestones - finance.biggo.com
Intellia Therapeutics Stock Price Forecast. Should You Buy NTLA? - StockInvest.us
Intellia Therapeutics (NTLA) Secures $400 Million As Investors Ask If The Upside Is Priced In - Yahoo Finance
Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength? - Eastern Progress
Should Intellia’s Milestone-Linked OrbiMed Loan Reshape Funding Risk Perceptions For Intellia Therapeutics (NTLA) Investors? - Yahoo Finance
Intellia Therapeutics Secures Major Non-Dilutive Loan Financing - TipRanks
Intellia Therapeutics Secures Up to $400 Million Five-Year Secured Credit Facility From OrbiMed - TradingView
FDA decision could unlock more of Intellia (NASDAQ: NTLA) $400M loan - stocktitan.net
41 new hires get Intellia stock awards that vest annually for 3 years - stocktitan.net
Intellia secures USD 400m non-dilutive debt facility ahead of lonvo-z commercial launch - AllSci
Intellia Therapeutics, Inc. Secures Non-Dilutive Debt Facility With OrbiMed For Up To $400 Million - marketscreener.com
NTLA Looks 4.3% Undervalued on GF Value™ Amid Strategic $400M Lo - GuruFocus
Intellia Therapeutics Enters $400 Million OrbiMed Term Loan Facility - marketscreener.com
Intellia Therapeutics Secures Up to $400 Million OrbiMed Debt Facility - citybiz
Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million - The Manila Times
Intellia Therapeutics Inc Stock (NTLA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):